Arrow declarations: which way is the law pointing?

In the life sciences field, patents are fundamental assets for companies developing new technologies and therapeutics. However, the way some companies have prosecuted their patent portfolios has caused issues for those seeking to create new products and therapies in developing fields.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

10x Genomics dealt major blow in sequencing fight

20 August 2026 Three disputed sequencing patents took the spotlight as the Federal Circuit weighed challenges to a trio of PTAB rulings.

Biotech

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

17 August 2026 Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains.

Biotech

Masimo keeps $634m smartwatch award and moves to appeal

21 July 2026 Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.

More features

UK appoints ex-engineer as new intellectual property Minister

Stris & Maher opens new Dallas office with partner hires

10x Genomics dealt major blow in sequencing fight

Former head of litigation at Nokia returns to Bird & Bird

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

Novartis scores UK win in high-stakes Entresto fight

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

The UPC plugs another gap in its procedural rulebook

Arrow declarations: which way is the law pointing?

More on this story

Editor's picks

Editor's picks

More features